The real question is if efficacy will be reported as part of Cohort 4 onwards. Your scenario is somewhat depressing otherwise Hoyland. I can see you are really down.
The company has said unofficially there is a high level of pharma interest and early efficacy could be a trigger point.
Ann: Chairman's Address to Shareholders, page-41
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)